iShares Genomics Immunology and Healthcare ETF (IDNA)

이 페이지는 영어 원문에서 AI로 기계 번역되었습니다. 영어 버전이 기준입니다. 영어 버전 읽기

정보 제공만을 목적으로 합니다. 재정적 조언이 아닙니다.

빠른 답변

iShares Genomics Immunology and Healthcare ETF (IDNA) has a last stored price of $40.83, as of the Oct 26, 2026 trading session. It has a 0.47% expense ratio and $150M in assets under management.

Holdings and weights below are as of Mar 15, 2026. In the stored portfolio snapshot, the largest listed holding is Moderna Inc (MRNA) at 6.57%, and the largest sector allocation is Healthcare at 97.5%.

iShares Genomics Immunology and Healthcare ETF (IDNA) ETF — Price, Holdings & Analysis

ETF 개요

IDNA aims to capture the growth potential of companies involved in genomics, immunology, and bioengineering. The ETF tracks an index composed of developed and emerging market companies believed to benefit from long-term growth and innovation in these fields. IDNA's portfolio consists of 52 holdings, with a significant allocation to the healthcare sector (97.5%). Top holdings include Moderna Inc (6.57%), Arcellx Inc (4.91%), and Ipsen SA (4.67%), reflecting a focus on innovative pharmaceutical and biotechnology companies. The fund's country exposure is heavily weighted towards the United States (60.5%), followed by France (8.6%) and Germany (7.3%). This targeted approach makes IDNA suitable for investors seeking specialized exposure to the genomics and immunology sub-sectors within the broader healthcare industry.

위험 지표

IDNA's concentrated sector allocation (97.5% in Healthcare) exposes it to sector-specific risks, meaning that the ETF's performance is highly dependent on the performance of the healthcare industry, particularly genomics and immunology companies. The ETF's beta of 1.35 (3-year) indicates that it is more volatile than the overall market. The fund's expense ratio of 0.47% will create a drag on returns, reducing overall performance by that amount annually. The fund's relatively small AUM of $0.15B could present liquidity risks, especially during periods of market stress. Investors should be aware of these factors when considering an investment in IDNA. Past performance does not guarantee future results.

베타: 1.35

운용보수율

0.47%

IDNA은(는) 무엇을 보유하고 있나요?

보유 종목	비중
Moderna Inc (MRNA)	6.57%
Arcellx Inc (ACLX)	4.91%
Ipsen SA (IPN.PA)	4.67%
Takeda Pharmaceutical Co Ltd (4502.T)	4.46%
Revolution Medicines Inc Ordinary Shares (RVMD)	4.35%
Bayer AG (BAYN.DE)	4.35%
Merck & Co Inc (MRK)	4.22%
Roche Holding AG (ROG.SW)	4.20%
GSK PLC (GSK.L)	4.18%
BioNTech SE ADR (BNTX)	3.89%

보유 종목 및 비중: 2026년 3월 15일 기준. 이 펀드 데이터는 45일 이상 지났습니다. 최신 보유 종목은 발행사에서 확인하세요.

펀드는 어떻게 배분되어 있나요?

섹터	비중
헬스케어	97.5%
현금 및 기타	1.7%
산업재	0.8%

국가	비중
미국	60.5%
프랑스	8.6%
독일	7.3%
일본	6.4%
스위스	5.6%
영국	4.1%
덴마크	3.1%
중국	2.1%
캐나다	0.9%
대한민국	0.8%

배당수익률

0.99%

iShares Morningstar Small-Cap Growth ETF (JKK) — 0.06% expense ratio
ARK Innovation ETF (ARKK) — 0.75% expense ratio
Invesco QQQ Trust, Series 1 (QQQ) — 0.18% expense ratio
State Street Energy Select Sector SPDR ETF (XLE) — 0.08% expense ratio
WisdomTree Emerging Markets ESG Fund (DVEM) — 0.32% expense ratio
Goldman Sachs ActiveBeta Emerging Markets Equity ETF (GEM) — 0.59% expense ratio
State Street SPDR Dow Jones Industrial Average ETF Trust (DIA) — 0.16% expense ratio
State Street Technology Select Sector SPDR ETF (XLK) — 0.08% expense ratio

iShares iBoxx $ High Yield Corporate Bond ETF (HYG) (Fixed Income) — 0.49% expense ratio
iShares 20+ Year Treasury Bond ETF (TLT) (Fixed Income) — 0.15% expense ratio
iShares MSCI UAE ETF (UAE) (Equity) — 0.59% expense ratio
iShares Climate Conscious & Transition MSCI USA ETF (USCL) (Equity) — 0.08% expense ratio
iShares Securitized Income Active ETF (SECU) (Fixed Income) — 0.40% expense ratio

질문 및 답변

What is IDNA and what does it track?

The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.

What is the expense ratio for IDNA?

The expense ratio for IDNA is 0.47%. This means that for every $10,000 invested in the ETF, $47 is deducted annually to cover the fund's operating expenses.

While this is a cost to consider, it's important to weigh it against the potential benefits of the ETF's focused investment strategy.

What are the top holdings in IDNA?

As of 2026-03-15, the top holdings in IDNA are Moderna Inc (6.57%), Arcellx Inc (4.91%), and Ipsen SA (4.67%). These companies represent a significant portion of the ETF's portfolio, reflecting its investment strategy focused on genomics, immunology, and healthcare.

The fund also holds Takeda Pharmaceutical Co Ltd (4.46%) and Revolution Medicines Inc Ordinary Shares (4.35%) among its top allocations.

Is IDNA a good long-term investment?

Whether IDNA is a suitable long-term investment depends on an individual's investment goals, risk tolerance, and time horizon. IDNA offers targeted exposure to the genomics, immunology, and healthcare sectors, which may experience growth due to technological advancements and demographic trends.

However, the ETF's concentration in these sectors also exposes it to sector-specific risks.

How does IDNA compare to similar ETFs?

IDNA differentiates itself through its specific focus on genomics, immunology, and healthcare. While other healthcare ETFs may offer broader exposure to the healthcare sector, IDNA targets companies involved in these specific sub-sectors.

The fund's expense ratio is 0.47%, which is comparable to other specialized healthcare ETFs.

Does IDNA pay dividends?

Yes, IDNA does pay dividends. The current dividend yield for IDNA is 0.99%. This means that for every $100 invested in the ETF, investors can expect to receive $0.99 in dividend payments annually.

It's important to note that dividend yields can fluctuate over time due to changes in the ETF's underlying holdings and market conditions.

면책 조항: 이 콘텐츠는 정보 제공만을 목적으로 하며 투자 조언을 구성하지 않습니다. 항상 자체 조사를 수행하고 재정 고문과 상담하십시오.

데이터는 정보 제공만을 목적으로 제공됩니다.

이 페이지는 기계가 작성했으며, 페이지별 사람 검수는 거치지 않았습니다. 편집 관리는 체계 차원에서 이루어집니다: 규칙과 출처를 점검하며, 개별 페이지는 점검하지 않습니다.